MedTrace Logo

Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus

NCT04240171 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-04-18

No results posted yet for this study

Summary

Research objectives:

The aim of the study to check the effect of Dapagliflozin versus Glimepiride on insulin regulated aminopeptidase (IRAPe), NT-Pro BNP and interleukin-34 (IL-34) in patients with type 2 diabetes mellitus, and associated it with insulin resistance.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Dapagliflozin 5Mg Tab

Dapagliflozin 5mg tablets daily

DRUG

Glimepiride 4Mg Tab

Glimepiride Tablets daily

Sponsors & Collaborators

  • Tanta University

    collaborator OTHER

  • Damanhour University

    lead OTHER

Principal Investigators

  • Nashwa EL-Gharabawy, Lecturer · Tanta University

  • Rehab Werida · Damanhour University, Faculty of Pharmacy

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2022-01-30
Completion
2022-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04240171 on ClinicalTrials.gov